Stay updated on CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Sign up to get notified when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.

Latest updates to the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page
- Check3 days agoChange DetectedThe page now shows a 403 Forbidden error screen with a minimal header and a Home link, replacing the study details. It indicates restricted access to the record rather than a content update to the study information.SummaryDifference18%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page shows a new revision tag (v3.6.6) replacing the previous v3.6.5, indicating a systems update to the page template rather than a change to study data.SummaryDifference0.0%

- Check45 days agoChange DetectedThe page revision number was updated from v3.6.4 to v3.6.5, indicating a small update to the study record.SummaryDifference0.0%

- Check60 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4, reflecting a minor update to the page system. No study content or results were changed.SummaryDifference0.0%

- Check81 days agoChange DetectedThe page now displays Revision: v3.6.3, replacing the previous v3.6.2. This reflects a new version of the page metadata rather than a substantive change to the information shown.SummaryDifference0.0%

- Check89 days agoChange DetectedPage metadata was updated from Revision v3.6.0 to v3.6.2, indicating a minor patch release of the page system. This update does not introduce changes to the study text or data.SummaryDifference0.0%

Stay in the know with updates to CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.